Some studies show that food costs go down by as much as 11% for those taking GLP-1s
In the phase II study, up to 46%-53% of AEs were of grade 3 or higher and 16%-25% led to treatment discontinuation [4,33-35]
Common criteria include: type 2 diabetes diagnosis with inadequate control on other medications, or BMI 27 kg/m with weight-related comorbidities (hypertension, sleep apnea, cardiovascular disease)
Palmero S, Leone M, Prati M, et al
The largest difference was seen among patients with heart failure vs those without (HR for discontinuation 0.81, 95% CI 0.79, 0.84) (Table 2)
It is not the length of the review process that is paramount, it is the quality of the review and the diligence of the reviewers. Daniel Drucker, Lunenfeld-Tanenbaum Research Institute Orforglipron is the first of several small molecule oral GLP-1 medicines